Close Menu

NEW YORK – Invitae on Monday announced a $200 million deal to acquire New Jersey-based Genosity and use its software and lab solutions to accelerate the development and decentralized market launch of somatic and germline oncology test offerings.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.